Stockscreener 앱 받기
3.84
5.19%
-0.21
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewswire Inc.
Foundation fighting blindness fund sells $2.75m in Opus Genetics stock - Investing.com
Form 4 Opus Genetics Inc For: 2 October By Investing.com - Investing.com Canada
A fund sells shares in Opus Genetics (IRD), leaving a 3.24M-share holding. - Stock Titan
Opus Genetics (IRD) CEO exercises 392K-share warrant in cashless deal - stocktitan.net
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com Nigeria
Opus Genetics Updates Clinical Data Presentation for OPGx-BEST1 Phase 1/2 Trial - Kalkine Media
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com Australia
Opus Genetics Gene Therapy OPGx-BEST1 Safe, Shows Improvement in 4 of 5 Patients - Minichart
Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook - TipRanks
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com Canada
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com UK
Opus Genetics Inc - Reuters
Opus Genetics CEO George Magrath Executes Warrant for 392,157 Shares via Cashless Exercise - Kalkine Media
Opus Genetics (NASDAQ: IRD) Plans Phase 3 Trial for OPGx-BEST1 in 2027 Following Promising Cohort 1 Results - Kalkine Media
Opus BEST1 and done? Gene therapy scores in rare eye diseases - BioWorld News
Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD) - Seeking Alpha
IRD Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $10 to $20 - Moomoo
Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating - marketscreener.com
Opus Genetics Stock Jumps 32% on Five-Patient Eye-Therapy Data—What IRD Must Prove Next - TechStock²
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Nigeria
IRD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Australia
Opus Genetics Shares Jump 30% as Low-Dose Gene Therapy Shows Vision Gains in Retinal Disease Trial - finance.biggo.com
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy TrialSlideshow - Seeking Alpha
Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial - marketscreener.com
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com South Africa
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - Yahoo Finance
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - Stocktwits
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com India
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Canada
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com UK
Wedbush raises Opus Genetics stock price target on FDA alignment - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
IRD: OPGX-BEST1 gene therapy showed robust safety and efficacy, supporting phase III advancement - TradingView
IRD Reiterates by BTIG -- Price Target Maintained at $12.00 - GuruFocus
Why Opus Genetics (IRD) Stock Is Up Today - quiverquant.com
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Opus Genetics Reports Positive Phase 1/2 Data for Gene Therapy OPGx-BEST1 - Minichart
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says - Benzinga
IRD: OPGX-BEST1 Phase 1/2 trial showed strong efficacy, safety, and FDA alignment for pivotal development - TradingView
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027 - Yahoo Finance
IRD: OPGX-BEST1 gene therapy showed robust safety and functional gains, supporting pivotal trial advancement - TradingView
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
Opus Genetics Reveals Interim Phase 1/2 BIRD-1 Trial Outcomes for OPGx-BEST1 - Kalkine Media
IRD Stock Jumps As Traders Target Gene Therapy Catalyst - timothysykes.com
IRD Stock Eyes Webcast Catalyst As Gene Therapy Data Nears - StocksToTrade
IRD Maintained by Chardan Capital -- Price Target at $13.00 - GuruFocus
4.22%
자본화:
|
볼륨(24시간):